A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

NCT04154072 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the drug NLY01 in people who have been recently diagnosed with Parkinson's disease.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 255 people

Who can join Ages 30–80 · all sexes

Timeline Started 2020-02 · est. completion 2023-02

Where 61 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT04154072 ↗

Description as written by the study sponsor.

This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.

Treatments tested

NLY01 Drug

exenatide and polyethylene glycol (PEG)
Vehicle Drug

Saline (Sodium Chloride)

Main thing measured	Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks
Sponsor	Neuraly, Inc.
Conditions studied	Parkinson Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04154072 ↗